1-benzyl-4-phenethylpiperidine-4-carbonitrile | 1432295-41-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-benzyl-4-phenethylpiperidine-4-carbonitrile
• 英文别名: 4-(2-Phenylethyl)-1-(phenylmethyl)-4-piperidinecarbonitrile；1-benzyl-4-(2-phenylethyl)piperidine-4-carbonitrile
• CAS: 1432295-41-4
• 化学式: C₂₁H₂₄N₂
• 分子量: 304.435
• InChiKey: KYQQBKCWBMKEAG-UHFFFAOYSA-N

物化性质

• 沸点：
  451.1±38.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-benzyl-4-phenethylpiperidine-4-carbonitrile 在 氨 、 氢气 作用下， 以 甲醇 为溶剂， 以90%的产率得到(1-benzyl-4-phenethylpiperidin-4-yl)methanamine
  参考文献：
  名称：

  Nonpeptide Small Molecule Agonist and Antagonist Original Leads for Neuropeptide FF1 and FF2 Receptors

  摘要：

  Neuropeptide FF1 and FF2 receptors (NPFF1-R and NPFF2-R), and their endogenous ligand NPFF, are one of only several systems responsible for mediating opioid-induced hyperalgesia, tolerance, and dependence. Currently, no small molecules displaying good affinity or selectivity for either subtype have been reported, to decipher the role of NPFF2-R as it relates to opioid-mediated analgesia, for further exploration of NPFF1-R, or for medication development for either subtype. We report the first nonpeptide small molecule scaffold for NPFF1,2-R, the guanidino-piperidines, and SAR studies resulting in the discovery of a NPFF1 agonist (7b, K-i = 487 +/- 117 nM), a NPFF1 antagonist (46, K-i = 81 +/- 17 nM), and a NPFF2 partial antagonist (53a, K-i = 30 +/- 5 nM), which serve as leads for the development of pharmacological probes and potential therapeutic agents. Testing of 46 alone was without effect in the mouse 48 degrees C warm-water tail-withdrawal test, but pretreatment with 46 prevented NPFF-induced hyperalgesia.

  DOI：

  10.1021/jm500989n
• 作为产物：
  描述：

  tert-butyl 4-cyano-4-phenethylpiperidine-1-carboxylate 在 caesium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 1.5h， 生成 1-benzyl-4-phenethylpiperidine-4-carbonitrile
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF
  [FR] COMPOSÉS HÉTÉROCYCLIQUES, MÉDICAMENTS CONTENANT LESDITS COMPOSÉS, LEUR UTILISATION ET LEURS PROCÉDÉS DE PRÉPARATION

  摘要：

  本发明涉及一般式(I)的化合物，其互变异构体和盐，特别是其与无机或有机酸和碱形成的药用盐，具有有价值的药理特性，特别是对上皮钠通道的抑制作用，以及其用于治疗疾病，特别是肺部和呼吸道疾病的用途。

  公开号：

  WO2013064450A1

文献信息

• HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF
  申请人：HECKEL Armin

  公开号：US20130109697A1

  公开（公告）日：2013-05-02

  The present invention relates to compounds of general formula (I) and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, and the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.

  本发明涉及一般式（I）的化合物及其互变异构体和盐，特别是其与无机或有机酸和碱形成的药用盐，具有有价值的药理特性，特别是对上皮钠通道具有抑制作用，并且用于治疗疾病，特别是肺部和呼吸道疾病。
• Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
  申请人：HECKEL Armin

  公开号：US20140228374A1

  公开（公告）日：2014-08-14

  The present invention relates to compounds of general formula (I) and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, and the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.

  本发明涉及一般式(I)的化合物及其互变异构体和盐，特别是与无机或有机酸和碱的药学可接受盐，具有有价值的药理学特性，特别是对上皮钠通道的抑制作用，以及其用于治疗疾病，特别是肺部和呼吸道疾病的用途。
• US8759349B2
  申请人：——

  公开号：US8759349B2

  公开（公告）日：2014-06-24
• US9920035B2
  申请人：——

  公开号：US9920035B2

  公开（公告）日：2018-03-20
• Nonpeptide Small Molecule Agonist and Antagonist Original Leads for Neuropeptide FF1 and FF2 Receptors
  作者：V. Blair Journigan、Christophe Mésangeau、Neha Vyas、Shainnel O. Eans、Stephen J. Cutler、Jay P. McLaughlin、Catherine Mollereau、Christopher R. McCurdy

  DOI：10.1021/jm500989n

  日期：2014.11.13

  Neuropeptide FF1 and FF2 receptors (NPFF1-R and NPFF2-R), and their endogenous ligand NPFF, are one of only several systems responsible for mediating opioid-induced hyperalgesia, tolerance, and dependence. Currently, no small molecules displaying good affinity or selectivity for either subtype have been reported, to decipher the role of NPFF2-R as it relates to opioid-mediated analgesia, for further exploration of NPFF1-R, or for medication development for either subtype. We report the first nonpeptide small molecule scaffold for NPFF1,2-R, the guanidino-piperidines, and SAR studies resulting in the discovery of a NPFF1 agonist (7b, K-i = 487 +/- 117 nM), a NPFF1 antagonist (46, K-i = 81 +/- 17 nM), and a NPFF2 partial antagonist (53a, K-i = 30 +/- 5 nM), which serve as leads for the development of pharmacological probes and potential therapeutic agents. Testing of 46 alone was without effect in the mouse 48 degrees C warm-water tail-withdrawal test, but pretreatment with 46 prevented NPFF-induced hyperalgesia.